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1. Introduction
The incidence of hepatocellular carcinoma (HCC) has increased exponentially. Liver cancer,
primarily HCC, has become the third cause of death from cancer worldwide and the ninth
cause of cancer deaths in the U.S.A. According to the center for disease control and prevention
statistics, the annual incidence of HCC has increased significantly to an average of 3.0 per
100,000 persons. The annual percentage change in incidence (APC) is 3.5% and the highest
APC was found in age group 50-59 years [1]. These statistics should be tampered with caution
as only biopsy proven HCC, histology code 8170 and 8175, were counted. This definitely
underestimates the scope of the disease.
2. Risk factors
While HCC may arise in healthy livers, the majority of cases develop in a back ground of
chronic liver disease i.e. cirrhosis which makes management even more challenging. Viral
hepatitis, both B (HBV) and C (HCV), cause 78% of primary liver cancer worldwide [1]. Other
risk factors include alcoholic liver disease [2], fatty liver disease (FLD) and non-alcoholic
steatohepatitis (NASH) [3, 4], hemochromatosis [5], primary biliary cirrhosis [6] and primary
sclerosing cholangitis [7]. Moreover, liver adenoma carries a 10% risk for malignant transfor‐
mation [8]. Tobacco smoking increases the incidence of HCC [9]. Fungi Aspergillus flavus
present in poorly stored grains produce Aflatoxin, an environmental hazard for HCC [10].
Hepatic venous occlusive disease has been implicated in HCC development in anecdotal case
reports [11].
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3. Who is eligible?
Orthotropic Liver transplantation (OLT) offers the prima facie cure for both HCC and liver
cirrhosis. Historically, while orthotropic liver transplantation (OLT) was at its infancy,
courageous attempts by Dr. Thomas Starzl and colleagues to offer OLT as a cure for HCC were
complicated by early recurrence [12]. As experience with OLT grew, researchers explored HCC
benchmarks that would guarantee comparable survival in tumor and non-tumor patients.
These efforts lead Mazzafero et al to Milan criteria. In HCC confined to the liver without
macrovascular invasion single tumor ≤ 5cm or up to three tumors each ≤ 3 cm had a five year
survival of 75% and a disease free survival of 83% [13]. Milan criteria results for OLT were
reproducible and ushered a new dawn for HCC patients. This success led to pushing the size
limits even further and University of California San Francisco (UCSF) criteria were introduced.
Such criteria include single tumor ≤ 6.5 cm or up to three tumors the maximum diameter of
which ≤ 4.5 cm or the total diameter ≤8cm. The one- and five -year survivals were 90% and
75% respectively [14].
It is intriguing that both criteria gained wide acceptance by the transplant community when
they focused on number and size of HCC lesions and ignored biological signature of the tumor
at a molecular level. To fuel the argument even more, according to data from Euro Transplant,
current imaging modalities when compared with explanted liver pathology were found to
underestimate by 10.4% or overestimate by 36.2% tumor size [15].
University of Toronto liver group took matters even further. They developed a protocol biopsy
for tumors up to 10cm in diameter and excluded poorly differentiated ones. Ablative therapies
were employed intensively to downstage/control the tumor while waiting for liver transplan‐
tation. Patient survival was similar for those with HCC within Milan criteria compared to
patients beyond such criteria [16].
Mazzafero et al recently reevaluated Milan criteria to find if they are restrictive to patients with
more tumor burden who may achieve similar outcomes. A multicenter data base was estab‐
lished. A retrospective analysis came up with the up-to-seven (Up-to-7) criteria; with 7 being
the sum of the size and number of tumors for any given hepatocellular carcinoma [17]. OLT
listing criteria are summarized in table 1.
Criteria UNOS TNM Definition
UNOS/ TNM I
II
III
IV
T1
T2
T3
T4a
T4b
N1,M1
1 nodule ≤ 1.9 cm
1 nodule, 2 to 5 cm, or 2 to 3 nodules, all≤ 3 cm
1 nodule > 5 cm or 2 to 3 nodules, 1 > 3 cm
≥4 nodules, any size; no gross vascular invasion
Any T with gross vascular invasion
Metastases
Milan 1 nodule ≤ 5cm or up to three nodules each ≤ 3cm
UCSF 1 nodule ≤ 6.5 cm or up to 3 nodules,
all ≤ 4.5 cm; total diameter ≤ 8 cm
Up-to-7 Diameter of the largest nodule (cm) + number of nodules ≤ 7
Table 1. Current criteria employed in liver allocation for HCC patients.
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4. Patient evaluation for OLT
Thorough history and physical examination by transplant surgeons and hepatologists are the
corner stone in assessment for OLT candidacy. Thereafter, patients undergo stringent testing
literally from head to toe.
4.1. Blood tests
An extensive laboratory tests are essential for patients’ evaluation. 1. Blood type and antibody
screen, panel of reactive antibody (PRA). 2. Full hepatitis profile, to include serum HCV-RNA
titers, HCV genotype, HBV-DNA, HBV-E antigen and antibody. 3. Full autoimmune markers
to include iron and copper studies, immune protein electropheresis. 4. Cancer markers, i.e.
alpha fetoprotein (AFP), CEA, PSA (prostate specific antigen) for males and CA 19-9. Another
diagnostic HCC marker has been recently introduced is descarboxyprothrombin (DCP) also
known as Prothrombin Induced by Vitamin K absence II (PIVKA II) [18]. 5. Complete blood
count (CBC), complete metabolic panel (CMP) to include magnesium and phosphate. 6.
Coagulation studies, i.e., PT/INR, fibrinogen levels and 7. Cytomegalovirus (CMV) status,
varicella titers, cryptococcal antibodies
4.2. Endoscopy
Esophago-gastro-duodenoscopy (EGD); to screen for esophageal/gastric varices, to identify
the extent of portal hypertensive gastropathy (PHG). This is important for bleeding risk
stratification while the patient is on the waiting list. Usually the esophageal varices are ligated
with rubber bands endoscopically.
Colonoscopy: All patients with cirrhosis older than age 35, or younger patients with higher
risk with history of colitis or family history of early colon cancer, undergo screening colono‐
scopy with prostatic digital exam being performed in men at the same time. Polyps are
identified and endoscopically removed. Patients with precancerous polyps and with history
of colitis will require further screening colonoscopies every few years following OLT.
Endoscopic retrograde cholangio-pancreatography (ERCP): may be required in certain cases
at the discretion of the transplant surgeons e.g. tumors at the porta hepatis or involving the
confluence of the bile ducts.
4.3. Imaging
Ultrasound of liver for HCC surveillance and to determine vessels patency by Doppler studies
Liver protocol 4- phase dynamic contrast computerized tomography (CT) of abdomen and
pelvis with oral and intravenous contrast is pivotal for HCC patients. Liver and spleen volumes
are computed, and the spinal bone density is detected during the procedure. Number, largest
diameter and location as well as macrovascular invasion are well documented to stratify the
tumor within transplant candidacy criteria. HCC has a characteristic pattern on 4-phase CT
scan. During the arterial phase it appears enhanced by taking up the i.v. contrast and in the
Liver Transplantation for Hepatocellular Carcinoma
http://dx.doi.org/10.5772/55374
23
following portal phase and delayed venous phase it appears hypointense the so called “wash
out” [19].
In addition, CT of lungs and brain as well as nuclear bone scan are obtained to look for potential
metastatic disease. Any extra hepatic disease precludes the patient from candidacy for OLT.
Magnetic resonance scan (MRI): may be required if the CT scan is not conclusive to further
delineate the diagnostic patterns of HCC. During gadolinium contrast dynamic MRI, on T1
weighted images the tumor appears hypointense, isointense or hyperintense. On T2 weighted
images HCC appears hyperintense on the arterial hepatic phase [20].
4.4. Cardiac assessment
In Cirrhotic patients, cardiomyopathy can compound the situation [21, 22]. All patients get
base line echocardiogram. Further testing such as cardiolyte cardiac stress testing and coronary
angiogram is at the discretion of the transplant cardiologist.
4.5. Pulmonary assessment
Chest roentgenogram (X R) is the base line test. Pulmonary function tests and ABG are ordered
as indicated e.g. ex-smokers, pulmonary hypertension (HTN) and hepatopulmonary syn‐
drome. Pulmonary HTN requires right sided heart catheterization and pressure measurement.
Hepatopulmonary syndrome is evaluated by bubble echocardiogram.
Sinus XR, panorex XR of teeth may be required according to history and physical examination.
Any sinus infection or dental caries has to be treated prior to transplantation.
4.6. Vaccinations
Prior to OLT, candidates should receive the following vaccines guided by their history of
previous vaccination 1.Hep A and B vaccination, if there is no evidence of prior immunity
indicated by antibody titers. 2. Pneunomax (pneumonia vaccine needs to be repeated every
five years). 3. Flu vaccination once a year. 4. PPD skin test for TB screening is also applied.
Also, Mammogram / Pap smear for women as appropriate for age are part of the pre transplant
evaluation tests.
4.7. Biopsy
The role of liver biopsy is contentious. The most dreaded complications are hemorrhage and
tumor seeding rate of 2%-3%. HCC recurrence rates were found to be higher in patients who
underwent liver transplant and had tumors >3cm, alpha feto protein >200ng/l and underwent
biopsy [23]. Liver biopsy is not routinely required for patients’ evaluation as long as the
imaging characteristics are diagnostic [24]. Correlation with serum alpha feto protein levels
can shed more light. In rare cases; lesion image guided biopsy is required for definitive
diagnosis. Liver biopsy can be done via trans jugular approach in coagulopathic patients.
Hepatic venous pressure gradient (HVPG) can be measured at the same time HVPG objectively
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assess the degree of portal hypertension [25]. As future research unfolds molecular signatures
and proteomics profiling of HCC; the role of pre transplant biopsy in liver transplant candidacy
for HCC patients will gain grounds. On a molecular level, proliferating indices, tumor
promoter genes, tissue invasion and metastases markers, angiogenic markers, growth factors
and genetic biomarkers and micro RNA have been implicated in diagnosis and prognostication
of HCC patients [26].
Barcelona clinic scheme for management of HCC offers a practical staging and treatment
strategy for HCC patients (Figure 1)
PEI, percutaneous ethanol injection; PS performance status; PST, performance status test; RF, radiofrequency; TTO,
time trade off.
Figure 1. Bracelona Clinic Scheme from Llovet et al [27]
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5. Diagnostic dilemmas
Often times, diagnosis of HCC is not that straight forward. Currently used markers such as
serum alpha feto protein and PIVKA II as well as imaging study can be equivocal. The lesion
may be too small to characterize with current imaging modalities. Also, hyperplastic or
macroregenrative nodules in cirrhotic livers can be difficult to distinguish from HCC. The
guide lines of the American Association for the Study of the liver disease (AASLD) recom‐
mends repeat ultrasound for lesions < 1cm at three month [28].
Positron emission tomography (PET) scan using F-18 fluoro-2-deoxy-D-glucose (FDG) has a
limited role in HCC diagnosis because of low sensitivity of 50%-55% [29].
Mixed tumors HCC/intrahepatic cholangiocarcinoma may have unconventional enhancement
patterns on CT and MRI scans. Usually, they are diagnosed on the explanted liver histopa‐
thology and carry worse survival than HCC [30, 31].
Even more, some small HCC are hypovascular and only diagnosed by biopsy or at the explant
pathological examination [32]
6. Care of HCC patients while on the waiting list:
6.1. Surveillance
Patients on the transplant waiting list with risk factors for HCC should be screened for HCC.
Once screening is positive they should join a surveillance protocol. For those who have HCC
enhanced follow up is required to monitor tumor development and treat as appropriate. Liver
ultrasound (US) and serum alpha feto protein at six months interval is the gold standard
according to AASLD are the main stay for surveillance. US reported sensitivity is between
65%- 80% and specificity is greater than 90% [33]. Nodular cirrhotic livers, small tumors and
obese patients impose a challenge for US. In such cases contrast enhanced dynamic CT or MRI
is invaluable for lesion characterization.
6.2. The concept of down staging and bridging therapy
Only 5% of HCC patients evaluated for OLT are amenable for transplant [34]. This led to
adoption of techniques to control tumor size. The rapidly evolving loco-regional therapies
have served well HCC patients by; (i) down staging the tumor to acceptable, within criteria,
size and number, (ii) disease control, while the patient is awaiting deceased donor OLT, so
called “bridging therapy” i.e. bridge to transplantation and (iii) and improving post OLT
survival with particular reference to tumor recurrence [35, 36]. Treatment has to be “tailored”
for each patient according to their Child-Pugh score, tumor burden and location and available
expertise and resources. T2 patients who are predicted to wait more than six months on the
list benefit from tumor therapy [35].Loco regional therapies include percutaneous alcohol
injection (PEI), thermal ablation such as radio frequency ablation (RFA) and microwave,
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chemotherapy delivered directly to the tumor tissue i.e. transarterial chemoembolization
(TACE), radiotherapy delivered in various ways such as transarterial Yttrium- 90, three
dimentional conformal radiotherapy and proton beam radiotherapy. In a prospective study
including forty eight patients, Graziadei et al reported tumor control and survival using TACE
for HCC patients while on the waiting list for OLT. The intention to treat 5- year survival was
93% and patients 5 year survival was 93%. Tumor recurred in one patient only, 2.4% rate [37].
Different modalities of radiotherapy are usually reserved for advanced HCC beyond trans‐
plant candidacy.
RFA as a bridge to transplantation was studied in a series of 52 patients with 87 HCC nodules.
Mean tumor diameter was 2.5 cm (range 0.4-5.07). Radiographic local tumor control was
achieved in 74 out of 87 tumors. In the 41 patients who received OLT; complete tumor necrosis
was found on explant pathology in 46 out of 70 lesions (65.7%) [38].
Combining two modalities can have a synergistic effect, ameliorate complications of each and
reduce the number of sessions to achieve tumor necrosis in patients with well compensated
liver functions.
Combination of RFA and PEI has increased the efficacy of RFA to produce coagulative necrosis
of HCC [39]. Another study employed TACE and laparoscopic RFA each as a single modality
or in combination for down staging a series of sixty one patients who had tumors exceeding
T2 stage i.e. a single lesion 2–5 cm or up to three lesions <3 cm. Tumor down staging was
achieved in 70.5% of patients and thirty five patients (57.4%) became candidates for OLT. The
explanted liver histology showed complete tumor necrosis in thirteen patients and down
staging to T2 in seventeen patients [40].
Irreversible Electroporation (IRE or Nano knife): This is an emerging technology that is still
undergoing clinical trials yet promising. Short pulses of high voltage current through electro‐
des inserted into the target tissue produces Nano size pores in the cell membrane that leads to
cell death. It has been validated in animal models [41] and limited number of patients with
variable inoperable tumors [42]. No intense heat is produced which makes it applicable for
tumors near major vessels, bile ducts and porta hepatis.
Molecular targeted therapies have emerged as an effective treatment for a variety of tumors.
Sorafineb is an oral multikinase inhibitor that blocks tumor cell proliferation by targeting raf/
MEK/ERK signaling. It also has antiangiogenic properties by targeting the vascular endothelial
growth factor receprtor-2/-3 and platelet derived growth factor beta tyrosine kinases [43].
Using the Markov model for decision making analysis [44], assuming that therapy starts on
the day of listing Sorafineb was found to be cost effective as compared to no therapy [45]. This
theoretical model does not take into account side effects of sorafineb particularly its antian‐
giogenic effect in proximity to major surgery as liver transplant. Clinical trials are awaited to
examine if sorafineb improves out comes and reduce post-transplant recurrence.
6.3. Liver resection as bridge to transplantation
In view of organ shortage and unpredictable waiting list time for deceased organs donors, liver
resection may be a rational option for patients with favorable lesions and well compensated
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livers. However, only a small percentage, 10%-15%, of HCC is resectable at time of presentation
due to advanced cirrhosis, extensive burden of the neoplasm or patients cardiopulmonary
status [46]. This rate of recetability is higher in Asian centers. One explanation is the higher
prevalence of HBV than HCV in Asia. In the natural history and hepatocarcinogensis of HBV,
HCC can develop in earlier stages of the disease than HCV. In a review of 271 patients who
are candidate for OLT, 98 of whom treated by liver resection multivariate analysis showed that
liver resection as a first line of treatment was a negative independent factor for disease free
survival as compared to primary OLT. Only 20% of the 98 patients who were suitable for
transplant but treated by resection received OLT later 17% for tumor recurrence and 3% for
liver decompensation [47].
In another series of 107 patients who underwent OLLT for HCC; 88 patients were within Milan
criteria. Of those 88 patients, 70 underwent primary OLT and 18 patients had liver resection
first before “salvage” transplantation. The mean time between liver resection and listing was
20 months (range 1-84). Indication for salvage transplant was tumor recurrence in 11 patients,
liver decompensation in 4 patients and high risk for recurrence in 3 patients. Three- year
survival (82 versus 82%) and five year survival (59%versus 61 %) were comparable in the two
groups [48].
It seems that the role of liver resection is limited to a highly selected group of HCC patients
with single small well differentiated lesion, no vascular invasion and well compensated
cirrhosis without portal hypertension. Therapeutic options has to be individualized taking into
consideration tumor biology, organ availability, patient preference, center practice and
regional rules for organ allocation.
7. Organ allocation
Shortage of deceased organ donors led to the development of organ allocation schemes to
ensure that such scarce resource is allocated to those patients who need it the most regarding
justice in distribution of organs amongst different patients groups. Model for end stage liver
disease (MELD) score is adopted by United Network for Organ sharing to prioritize patients
on the waiting list. MELD was originally developed to predict mortality for patients with portal
hypertension undergoing transjugular intrahepatic porto-systemic shunts (TIPS). MELD
mathematical equation is 0.957 x log (serum creatinine, mg/dl+ 0.378 x log (serum bilirubin,
mg/dl + 1.120 log (INR) + 0.643 [49]. Patients who have T2 (2-5 cm) HCC tumors within Milan
criteria gain 22 exceptional MELD points. If the patient with stable disease is still waiting for
OLT for three month the exceptional points are increased to 25 [50]. These exceptional points
led to an exponential increase in the number of registered HCC patients for OLT [51].
8. Living liver donors
One of the major challenges facing the liver transplant community is donor organ shortage
especially in Asia where deceased organ donation is limited. High mortality while on the
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transplant waiting list compounds the challenge. Living donor liver transplant (LDLT)
programs have emerged as one of the solutions to bridge the gap between the overwhelming
demand and the limited supply. Live donation offers many advantages to the recipients; it
eliminates waiting time on the list, offers the convenience of scheduling the operation at an
opportune time and optimal short cold ischemia time. Nevertheless, it subjects healthy donors
to a major operation with possible 1% mortality and significant morbidity [52]. Healthy
volunteers for donation undergo scrutinizing tests to validate their candidacy for liver
donation including psychological evaluations. In a large number of living donor volunteers
who step forward for evaluation; liver anatomical morphology and/or anomalies prohibit
donation [53]. Pediatric patients usually receive left lateral segment (segments II and III) while
adult recipients may receive right or left lobe depending on the liver volume, size and
recipients' weight and height.
Advances in imaging technology allow calculating the liver volume of each lobe and also each
segment as desired [54]. Actual knowledge of liver parenchymal, vascular and biliary anatomy
is crucial to minimize operative and post-operative complications [55].Computer assisted and
image guided surgery have contributed to the safety and precision of the donor operation.
Two dimensional CT scans are converted to three dimensional (3D) images that delineate the
vascular and biliary anatomy. Pre-operative planning and virtual resection have contributed
significantly to liver resection safety. Also 3D pre-operative images guide venous reconstruc‐
tion and help surgeons avoid venous congestion [56].
In a series of 236 patients who received LDLT for HCC and 172 patients outside Milan criteria;
the recurrence rate was 12.7%. One and three year recurrence free survival was 72.7% and
64.7% respectively. Independent risk factors for tumor recurrence were serum alpha feto
protein level, tumor size, bilobar distribution, tumor differentiation and vascular invasion.
[57]. Vakili et al found that in HCC tumor recurrence is higher in LDLT recipients than in
deceased donor recipients; 28.6 % versus 12.1% respectively. Paradoxically one- and five -year
patient and graft survival in LDLT were 94% and 81% [58]. This higher HCC recurrence rate
in LDLT may be explained by the time lag bias. Longer waiting time for deceased donors liver
recipients discloses tumors with aggressive biology and patients drop out from the list.
Another explanation may be the milieu of tumor regeneration with outpouring of growth
factors that enhances tumor recurrence. Whether LDLT enhances recurrence remains contro‐
versial. In a well matched cohort of LDLT and DDLT recipients for HCC; the survival and
recurrence rate were similar in the two groups. Microvascular invasion was the only predictor
of tumor recurrence using regression analysis [59]. In a series of 221 LDLT for HCC; one of the
significant factors for tumor recurrence is tumor size and number. Three-year HCC recurrence
rates were 13.6% within Milan criteria, 20% within UCSF criteria and 51.6% beyond UCSF
criteria [60].
9. Split livers
Another solution that was improvised to expand the donor pool in face organ shortage is split
livers. The deceased donor liver is split to transplant two patients. Usually, the split incurs left
Liver Transplantation for Hepatocellular Carcinoma
http://dx.doi.org/10.5772/55374
29
lateral segment (segment II and III) for a pediatric recipient and the extended right (segments
IV-VIII) for an adult recipient. Survival of split liver transplant is comparable to those of whole
graft [61, 62]. In vivo, also in situ, splitting offers better out comes than ex vivo splitting in terms
of post-operative complications and graft dysfunction [63]. In a series of six patients with HCC
who received split liver grafts with a median follow up of 20 months no recurrence was
observed [64]
In both approaches of reduced grafts, LDLT and split liver transplant, size matching is an
important consideration in LDLT. A ratio of graft volume to standard liver volume of > 30%
is crucial for adequate post-transplant hepatic function [65].
Small for size syndrome has been described in LDLT recipients when the graft liver volume
is too small for the recipient [66]. Graft failure was attributed to high portal blood flow. It was
described mainly in left lobe recipients. One of the protective strategies is of portal blood
modulation. This is achieved by partial diversion of the portal blood flow to the inferior vena
cava (IVC) by anastomosing the right portal branch to the right hepatic vein [67].
Also, large for size syndrome is a result of size mismatch when the abdominal cavity of the
recipient cannot accommodate comfortably the graft [68]. Graft compression exaggerates the
ischemia reperfusion injury. Using synthetic grafts such as gortex mesh or alloderm to close
the abdominal wall without tension increase the chances of postoperative infections
10. Immunosuppression
Immunosuppression remains the drawback of transplantation. Immunosuppression entails
substantial cost, compliance, vulnerability to a wide scope of infections and side effects and
de novo malignancies.
Steroids, calcinurin inhibitors (CNIs) including cyclosporine and tacrolimus, mycofenolate
mofetil and mammalian target of rapamycin (mTOR) inhibitor (rapamycin) remain the main
agents for maintenance therapy. Each of those agents has a myriad of side effects. Usually two
to three agents are used in combination in a trial to reduce the dose of each and subsequently
minimize size effects. Major side effects of CNIs are renal toxicity, hypertension, diabetes
mellitus and neurotoxicity. Serum levels have to be monitored frequently and dose adjusted
accordingly. Major side effects of sirolimus are impaired wound healing, hypercholesterole‐
mia, anemia, thrombocytopenia and mouth ulcers.
Steroids have a wide range of side effects including increased susceptibility to infections,
diabetes mellitus, hypertension, impaired wound healing and cataracts to name a few. Early
withdrawal of steroids is thought to be beneficial especially in HCV patients to control
recurrence of viral hepatitis. One study found that early steroid withdrawal had no influence
on HCV recurrence but reduced the incidence of post OLT diabetes mellitus [69].
In quest for the holy grail of transplantation, immune tolerance, induction immunosuppressive
therapies have evolved to include various biological agents that are either monoclonal
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(muromonab-CD3, daclizumab, basiliximab, alemtuzumab) or polyclonal antithymocyte
globulin [equine] or antithymocyte globulin [rabbit] antibodies. These agents can be further
classified to depleting agents and non-depleting agents according to their ability to deplete
lymphocyte. Depleting agents include antithymocyte globulin and anti CD52, alemtuzumab
(Campath). Antilymphocyte globulin causes T lymphocyte lysis through a complement –
dependent manner while alemtuzumab causes lymphocyte lysis by binding to CD 52, a
receptor present on virtually all B and T lymphocytes. Non depleting agents include basilixi‐
mab (simulect) and Daclizumab (zenapax). Both agents are receptor antagonists that have high
affinity to alpha subunits of IL-2 receptor, also known as CD- 25. IL-2 antagonism prevents T
lymphocyte activation and proliferation.
The rational of induction immunotherapy is immunomodulation to curb allograft rejection,
reduce the steroid and CNIs doses and subsequently minimize the side effects. The initial
results are encouraging. In a randomized controlled study using rabbit antithymocyte globulin
(RATG) for induction therapy; steroids were avoided, rejection episodes were less and HCV
recurrence was decreased [70]. Using interlukin-2 receptor antibody (basiliximab) for induc‐
tion allowed early withdrawal of the steroids and reduction of the tacrolimus dose. This was
associated with fewer incidences of post OLT diabetes and acute cellular rejection [71].
New immunosuppression agents or immunomodulation agents for a better term, are being
developed and tested in clinical trials involving mainly kidney transplant. Voclosporin
(ISA247) is a novel CNI that proved to have similar effectiveness to Tacrolimus with potential
reduction in new onset diabetes mellitus [72]. Belatacept is a chimeric fusion protein that blocks
costimulation of T-lymphocytes was comparable to cyclosporine plus an improved renal
function and fewer metabolic complications but increased risk of post-transplant lymphopro‐
liferative disease [73]. Everolimus is an mTOR inhibitor, a rapamycin analogue. In a random‐
ized controlled study involving liver transplant recipients, everolimus was found to impart
same efficacy and better renal function when used with low dose tacrolimus compared to
standard dose tacrolimus [74].
11. Tumor recurrence
Tumor recurrence remains a potential threat to HCC patients who receive liver transplants.
HCC recurrence can be as high as 40% following OLT [75]. Researchers at University of
Western Ontario, Canada looked at variables that significantly influence HCC recurrence post
OLT. In a total of 75 cases 20 cases had recurrence within a follow up mean of 8 years. Tumor
criteria were assessed based on the explant pathology. Those patients within UCSF criteria had
a recurrence rate of 67% versus 12% of those within Milan criteria (p <0.001). Also, 5-year
survival was lower in UCSF group compared to Milan group 15% versus 83% respectively (p
<0.001) [76].
Immunosuppression regimen may have an influence on tumor recurrence. Decaens and
colleagues found out that induction therapy with lymphocyte antibody (ATG) or anti CD3
antibody is a risk factor for HCC recurrence after OLT [77].
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The antiproliferative property of rapamycin (sirolimus) makes it an attractive option for HCC
patients in an attempt to reduce tumor recurrence and reduce the long term side effects of
CNIs. In an animal model using human HCC tumor (LCI-D20) cell line; rapamycin alone or
in combination with sorafineb was found to inhibit primary tumor growth and lung metastasis
[78]. In one matched -cohort of HCC patients who underwent OLT; one group received
sirolimus and the other group received tacrolimus based immunosuppression. Three-year
recurrence free survival in the sirolimus group was 86% compared to 56% in the tacrolimus
based group (p < 0.04) [79]. This issue remains controversial specially that HCC patients fall
under different criteria; Milan, UCSF and beyond UCSF and immunosuppression protocols
can vary great deal. Most publications in favor of the hypothesis that using sirolimus for post
OLT immunosuppression reduces tumor recurrence are retrospective and level 3-4 evidence
according to center for evidence based medicine, Oxford, U.K. [80]. This highlights the need
for prospective, well designed, multicenter studies to solve this debate.
In a multivariate analysis involving 109 patients who underwent OLT, Lai et al found that
exceeding UCSF criteria (p =0.003) and microvascular invasion (p= 0.007) were independent
risk factors for recurrence [81].
Up- to -7 criteria was tested in a recent study involving 479 HCC patients who received OLT
at two different centers. In 335 patients who met up -to -7 criteria; the calculated recurrence
probability at 1-, 3- and 5- year was 4%, 8% and 14%. Multivariate analysis showed that only
macrovascular invasion and tumor grade were significant predictors of survival [82].
Many liver transplant centers confirm that tumor biology plays an important role post OLT
survival and recurrence. Crude markers such as degree of differentiation (G1-G4) and
microvascular invasion are increasingly found to be predictors of recurrence [83]. Also, tumor
numbers, diameter of the largest lesion and donor age were significant predictors of recurrence
[84]. Another study included 48 patients found that pre transplant AFP slope greater than 50
µg/L per month is associated with higher rate of one year recurrence [85].
The fact that tumor recurs in a subgroup of transplant patients after removal of the only source
i.e. HCC bearing liver coupled with the growing evidence of the role or vascular invasion, both
micro and macro, as a risk factor for recurrence supports the hypothesis of circulating tumor
cells (CTC) role in recurrence [86].
12. Conclusion and future look
In conclusion, the major strides in liver transplantations made it a valuable therapeutic option
for a subset of carefully selected HCC patients. Studies continue to identify tumor criteria that
yield post-transplant outcomes comparable to those of non-tumor transplant patients. Tumor
signature at a molecular level is a promising field to further characterize HCC in the context
of liver transplantation. Pre transplant loco-regional therapies, especially for T2 HCC patients
who are anticipated to wait more than six months, provide tumor control and possibly improve
outcomes. Ongoing research in surgical technology adds new items to the surgical armamen‐
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tarium such as image guided surgery, Nano knife that makes liver surgery safer and more
effective. Advances in immunomodulation are coming up with promising new agents that are
more efficient and with fewer side effects.
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